Breaking News Instant updates and real-time market news.

COUP

Coupa Software

$134.38

-4.46 (-3.21%)

, GSM

Ferroglobe

$1.24

-0.075 (-5.70%)

18:50
09/03/19
09/03
18:50
09/03/19
18:50

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Coupa Software (COUP) up 9.9%... Ferroglobe (GSM) up 4.0%. ALSO HIGHER: Puma Biotechnology (PBYI) up 10.3% after getting FDA orphan drug designation for Nerlynx... Box (BOX) up 6.7% after disclosing 7.5% activist stake from Starboard... Lumber Liquidators (LL) up 4.2% after speculation that its founder seeks talks about possible Cabinets to Go combination. DOWN AFTER EARNINGS: Safe Bulkers (SB) down 10.3%... Tyson Foods (TSN) down 6.0% after cutting FY19 guidance... HealthEquity (HQY) down 3.8%... eGain Corp (EGAN) down 1.5%. ALSO LOWER: Superior Industries (SUP) down 17.3% after suspending dividend payout... Aridis Pharma (ARDS) down 5.5% after mixed shelf offering... Redwood Trust (RWT) down 3.1% after equity offering... Okta (OKTA) down 2.1% after convertible note offering. Movers as of 18:30ET.

COUP

Coupa Software

$134.38

-4.46 (-3.21%)

GSM

Ferroglobe

$1.24

-0.075 (-5.70%)

PBYI

Puma Biotechnology

$10.43

-0.33 (-3.07%)

BOX

Box

$14.87

0.23 (1.57%)

LL

Lumber Liquidators

$9.29

-0.11 (-1.17%)

SB

Safe Bulkers

$2.13

0.08 (3.90%)

TSN

Tyson Foods

$93.25

0.19 (0.20%)

HQY

HealthEquity

$58.00

-1.36 (-2.29%)

EGAN

eGain

$7.56

0.35 (4.85%)

SUP

Superior Industries

$2.61

-0.14 (-5.09%)

ARDS

Aridis Pharmaceuticals

$11.01

-1.39 (-11.21%)

RWT

Redwood Trust

$16.67

0.06 (0.36%)

OKTA

Okta

$128.18

1.66 (1.31%)

  • 03

    Sep

  • 03

    Sep

  • 03

    Sep

  • 04

    Sep

  • 04

    Sep

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 10

    Sep

  • 15

    Sep

  • 19

    Sep

  • 23

    Sep

  • 25

    Sep

  • 01

    Oct

  • 10

    Oct

  • 15

    Oct

  • 12

    Dec

  • 16

    Dec

  • 04

    Sep

COUP Coupa Software
$134.38

-4.46 (-3.21%)

08/26/19
BOFA
08/26/19
NO CHANGE
Target $168
BOFA
Buy
Coupa Software price target raised to $168 from $140 at BofA/Merrill
BofA/Merrill analyst Brad Sills raised his price target for Coupa Software to $168 from $140 saying he expects the company to report "strong" Q2 billings upside on September 3. After speaking to key system integrator partners, the analyst sees from core procurement strength and early traction with Coupa Pay. He regards Coupa as a top pick and keeps a Buy rating on the shares.
08/01/19
WEDB
08/01/19
INITIATION
Target $168
WEDB
Outperform
Coupa Software initiated with an Outperform at Wedbush
Wedbush analyst Steve Koenig started Coupa Software with an Outperform rating and $168 price target. The "large" market of business spend management and "relatively weak" competition create a "long runway" for sustained sales growth and margin expansion for the company, Koenig tells investors in a research note.
07/22/19
KEYB
07/22/19
NO CHANGE
Target $171
KEYB
Overweight
Coupa Software price target raised to $171 from $136 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Coupa Software to $171 from $136 and maintained an Overweight rating. In a research note to investors, Bracelin says Coupa that by leveraging over $400B of annual spend across more than 1,000 customers on the Business Spend Management platform, he estimates the new Coupa Pay digital payment opportunity could grow to $270M by fiscal 2024 from $3.7M in fiscal 2020, and thinks Coupa Pay could alone be worth an incremental $35 per share.
07/24/19
DBAB
07/24/19
INITIATION
Target $150
DBAB
Hold
Coupa Software initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Michael Turrin started Coupa Software with a Hold rating and $150 price target. The analyst is positive on Coupa's "best-in-class business fundamentals" but is neutral on the shares given the current multiple.
GSM Ferroglobe
$1.24

-0.075 (-5.70%)

02/14/19
JEFF
02/14/19
DOWNGRADE
Target $2.7
JEFF
Hold
Ferroglobe downgraded to Hold from Buy at Jefferies
Jefferies analyst Martin Englert downgraded Ferroglobe to Hold and lowered his price target for the shares to $2.70 from $3.
02/14/19
JEFF
02/14/19
DOWNGRADE
Target $2.7
JEFF
Hold
Jefferies downgrades Ferroglobe to Hold on lack of catalysts
Jefferies analyst Martin Englert downgraded Ferroglobe to Hold from Buy and lowered his price target for the shares to $2.70 from $3.00. The catalysts potentially driving upward revisions have failed to materialize, Englert tells investors in a research note. The analyst, who thought capacity curtailments could boost silicon prices and higher aluminum scrap could dissuade the shift away from primary silicon and Mn-alloys, now sees a "lack of foreseeable catalysts."
11/28/18
JPMS
11/28/18
NO CHANGE
JPMS
Overweight
Ferroglobe 62% selloff yesterday 'appears overdone,' says JPMorgan
JPMorgan analyst Michael Gambardella lowered his estimates for Ferroglobe and withdrew his price target o reflect greater than expected price declines and shipments for the company, with the impact on earnings expected to persist in the near term. However, the analyst does not expect spot prices to fall much further and does not expect costs to continue to have a negative impact on the company's earnings. He maintains an Overweight rating on the stock and thinks yesterday's 62% decline "appears overdone."
11/28/18
RILY
11/28/18
NO CHANGE
Target $4
RILY
Buy
Ferroglobe price target lowered to $4 from $14.50 at B. Riley FBR
B. Riley FBR analyst Sarkis Sherbetchyan lowered his price target for Ferroglobe to $4 from $14.50 after the company's Q3 results missed his expectations. His new price target reflects an unchanged multiple of eight times estimated fiscal 2019 EBITDA. The analyst keeps a Buy rating on the shares.
PBYI Puma Biotechnology
$10.43

-0.33 (-3.07%)

08/09/19
LEHM
08/09/19
NO CHANGE
Target $9
LEHM
Underweight
Puma Biotechnology price target lowered to $9 from $21 at Barclays
Barclays analyst Gena Wang lowered her price target for Puma Biotechnology to $9 from $21 and reiterates an Underweight rating on the shares following the company's Q2 results. The analyst continues to see limited growth potential for Nerlynx in multiple indications, including extended adjuvant, metastatic breast cancer and HER2 mutated tumors.
05/29/19
GSCO
05/29/19
NO CHANGE
Target $24
GSCO
Neutral
Puma Biotechnology price target lowered to $24 from $29 at Goldman Sachs
Goldman Sachs analyst Paul Choi lowered his price target for Puma Biotechnology to $24 from $29 price target and keeps a Neutral rating on the shares. The analyst believes a takeover of Puma is less likely since it has "struggled to execute" on the commercial launch of Nerlynx. He removed the M&A component from his valuation framework given the "erratic commercial uptake" of the drug.
05/10/19
SBSH
05/10/19
DOWNGRADE
Target $24
SBSH
Neutral
Puma Biotechnology downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Puma Biotechnology to Neutral from Buy and lowered his price target for the shares to $24 following the company's Q1 results.
05/10/19
JPMS
05/10/19
NO CHANGE
Target $19
JPMS
Underweight
Puma Biotechnology price target lowered to $19 from $27 at JPMorgan
JPMorgan analyst Cory Kasimov lowered his price target for Puma Biotechnology to $19 from $27 saying Q1 Nerlynx sales of $46M fell well below his and Street expectations. Experience suggests that" stalled launches aren't quick and/or easy to fix," Kasimov tells investors in a post-earnings research note. He reiterates an Underweight rating on Puma Biotechnology.
BOX Box
$14.87

0.23 (1.57%)

08/29/19
DADA
08/29/19
NO CHANGE
Target $17
DADA
Buy
Box price target lowered to $17 from $19 at DA Davidson
DA Davidson analyst Rishi Jaluria lowered his price target on Box to $17, saying that while the company beat on Q2 earnings, the underlying metrics were less "rosy" with slowing growth in billings, decline in retention rates, below-consensus deferred revenues, and a slide in the number of $500K+ deals. The analyst still keeps his Buy rating on Box longer term, citing the company's "differentiated technology" and new products like Shield, Skills, and Relay, adding that at 2.8-times enterprise value to expected 2020 revenue, the stock offers "solid risk-reward".
08/29/19
CHLM
08/29/19
DOWNGRADE
Target $15
CHLM
Hold
Box downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Chad Bennett downgraded Box to Hold from Buy and lowered his price target for the shares to $15 from $22. The company remains in a "no-man's land" for investors, and the time has come for "material changes" in leadership, Bennett tells investors in a research note following the company's Q2 results. The analyst says he's never come across a company that is a leader in a $40B total addressable market and "continues to mis-execute so badly." Box is "potentially an activist investor's dream," but five of the nine board members being founders or venture capitalizes presents a a "bit of a roadblock," says Bennett. He sees the stock as a "value trap" until material changes are taken.
08/29/19
FANA
08/29/19
DOWNGRADE
Target $14
FANA
Neutral
Box downgraded to Neutral from Outperform at First Analysis
First Analysis analyst Terry Kiwala downgraded Box to Neutral from Outperform and lowered his price target for the shares to $14 from $22. The analyst hoped the company's Q2 results and guidance would provide evidence that its revenue growth could accelerate beyond the 10%-12% growth that guidance implies for the second half of 2019. However, he now has reduced confidence in this prospect. While the number of Box's over-$100,000 deals signed in Q2 was up 36% year-over-year, the number of over-$500,000 deals signed was down substantially year-over-year and over-$1M deals signed were flat, Kiwala tells investors in a research note. The analyst cites continued sales uncertainty for his downgrade to Neutral.
08/29/19
08/29/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Box (BOX) downgraded to Neutral from Outperform at First Analysis and to Hold from Buy at Craig-Hallum. 2. G-III Apparel (GIII) downgraded to Hold from Buy at Stifel with analyst Jim Duffy saying his more cautious outlook reflects "shocks" to his fiscal 2021 earnings estimates from tariffs on China manufactured goods sold in the U.S. 3. Tapestry (TPR) and Movado (MOV) downgraded to Market Perform from Outperform at Cowen. 4. Solid Biosciences (SLDB) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying the stock has nearly doubled over the last month without anything fundamental changing, which has opened up a sell opportunity. 5. Casey's General Stores (CASY) downgraded to Underperform from Sector Perform at RBC Capital with analyst Irene Nattel citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LL Lumber Liquidators
$9.29

-0.11 (-1.17%)

05/01/19
05/01/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Outperform from Neutral at Credit Suisse with analyst William Featherston saying the stock has underperformed peers by about 30% year to date, driven by the unwind of winners from last year that occurred in January/February, and concern it makes a large, corporate acquisition. However, Featherston thinks concerns are overdone. 2. Lumber Liquidators (LL) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying most reputational and legal issues are behind the company and financial performance is more "stable." 3. Seagate (STX) was upgraded to Buy from Hold at Benchmark and to Buy from Hold at Craig-Hallum. 4. Corning (GLW) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan saying the pullback in shares provides a buying opportunity. 5. Ingersoll-Rand (IR) upgraded to Buy from Hold at Deutsche Bank with analyst Nicole DeBlase saying the deal combining Gardner Denver with Ingersoll-Rand's Industrial segment makes strategic sense and creates clear cost synergy opportunities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/01/19
05/01/19
UPGRADE
Target $16

Outperform
Lumber Liquidators upgraded to Outperform at Raymond James
As previously reported, Raymond James upgraded Lumber Liquidators to Outperform from Market Perform and established a $16 price target following the Q1 beat. Analyst Budd Bugatch said most reputational and legal issues are behind the company and financial performance is more "stable. The analyst is also constructive on the performance and plans for the Altamonte Springs prototype and improved store productivity.
05/01/19
RAJA
05/01/19
UPGRADE
RAJA
Outperform
Lumber Liquidators upgraded to Outperform from Market Perform at Raymond James
06/05/19
RAJA
06/05/19
NO CHANGE
RAJA
Outperform
Tariffs creating new 'headaches' for Lumber Liquidators, says Raymond James
Raymond James analyst Budd Bugatch tells investors in a research note the trade argument between the U.S. and China and the resulting tariffs are providing a new "headache" for Outperform-rated Lumber Liquidators at a time when its leadership was beginning to focus exclusively on operating, growing, and improving its business. Bugatch says management noted in its 2018 10-K that it sourced about 47% of its products from China last year, and sees potential proactive actions with vendors and/or merchandise prices to offset tariffs. He thinks most of the bad news about tariffs has been priced-in by the "skittish" market.
SB Safe Bulkers
$2.13

0.08 (3.90%)

02/20/19
MAXM
02/20/19
NO CHANGE
Target $3.5
MAXM
Buy
Safe Bulkers price target lowered to $3.50 from $6 at Maxim
Maxim analyst James Jang lowered his price target on Safe Bulkers to $3.50 after its in-line Q4 results and citing concerns around the "ongoing U.S.-China trade war and slowdown in Chinese seaborne coal demand" in the first half of 2019. The analyst is keeping his Buy rating on the stock, saying his new price target "still represents significant upside".
11/09/18
JEFF
11/09/18
UPGRADE
Target $3.5
JEFF
Buy
Jefferies calls Safe Bulkers undervalued, upgrades shares to Buy
Jefferies analyst Randy Giveans upgraded Safe Bulkers to Buy from Hold with an unchanged price target of $3.50. The stock has traded down recently with capesize rates amid Australian iron ore supply disruptions, but Capesizes make up only four of Safe Bulkers' 41-vessel fleet, Giveans tells investors in a research note. The analyst points out that smaller asset class spot rates, time charter rates, and asset values "remain firm." He thinks the shares, currently trading at a 20% discount to estimated net asset value, are undervalued. Safe Bulkers shares should perform well as rates improve in the coming weeks/months, says Giveans.
10/18/18
10/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying Nike represents an "already dominant, legacy global brand that is now aggressively embracing the power of digital to enhance most facets of its business." 2. United Continental (UAL) upgraded to Outperform from Neutral at Macquarie and to Overweight from Equal Weight at Stephens. 3. Generac (GNRC) upgraded to Neutral from Sell at Goldman Sachs with analyst Jerry Revich saying the company's organic growth outlook is improving amid rising power disturbances. 4. Proteostasis (PTI) upgraded to Outperform from Sector Perform at RBC Capital with analyst Brian Abrahams citing an "impressive" set of data from its phase 2 cystic fibrosis doublet trial. 5. Safe Bulkers (SB) upgraded to Outperform from In Line at Evercore ISI with analyst Jonathan Chappell saying the disconnect between dry bulk equity prices and spot rates continues to widen due to global trade/macro fears. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/18
JEFF
11/09/18
UPGRADE
Target $3.5
JEFF
Buy
Safe Bulkers upgraded to Buy from Hold at Jefferies
Jefferies analyst Randy Giveans upgraded Safe Bulkers to Buy with a $3.50 price target.
TSN Tyson Foods
$93.25

0.19 (0.20%)

08/06/19
MZHO
08/06/19
NO CHANGE
Target $95
MZHO
Buy
Tyson Foods price target raised to $95 from $89 at Mizuho
Mizuho anlayst Jeremy Scott raised his price target for Tyson Foods to $95 from $89 following yesterday's fiscal Q3 results and keeps a Buy rating on the shares. The stock rallied on favorable guidance for both this year and next, including management's outlook that all operating segments would match or beat fiscal 2019 results, including prepared food, Scott tells investors in a research note.
06/26/19
MZHO
06/26/19
NO CHANGE
MZHO
DOJ intervening in poultry case not entirely surprising, says Mizuho
Mizuho analyst Jeremy Scott said it isn't entirely surprising to see the DOJ intervene in the Maplevale civil case against chicken producers given the DOJ's interest in the case previously became apparent in Tyson's (TSN) 10-Q filling in May. Scott said the investigation launch does not necessarily suggest that there is new corroborating evidence, though it does raise the stakes for company legal teams and builds on an already distracting and costly process in the courts that will likely take two years or more to reach a conclusion. Other protein stocks include Hormel (HRL), Pilgrim's Pride (PPC) and Sanderson Farms (SAFM).
06/18/19
MZHO
06/18/19
NO CHANGE
MZHO
Mizuho lowers near-term estimates across protein space
Mizuho analyst Jeremy lowered his near-term estimates across the protein space to reflect higher feed costs. Progress reports and persistent flooding in the Midwest suggest "unrecoverable gaps" to projected harvest acreage and a tighter supply in the U.S., Scott tells investors in a research note. Further, a "substantial drop" in soy demand from China and corn demand from other African Swine Fever-impacted regions should help offset the U.S. supply shortfall, adds the analyst. Scott reduced his estimates to reflect the risk of feed cost inflation over the next twelve months, but maintains Buy ratings on Tyson Foods (TSN), Pilgrim's Pride (PPC) and Sanderson Farms (SAFM).
06/21/19
LEHM
06/21/19
NO CHANGE
Target $100
LEHM
Overweight
Tyson Foods price target raised to $100 from $85 at Barclays
Barclays analyst Benjamin Theurer raised his price target for Tyson Foods to $100 from $85 and keeps an Overweight rating on the shares. Diversified animal based protein companies seem set to benefit most from the worsening African Swine Fever situation in China and other countries in Southeast Asia, Theurer tells investors in a research note. Tyson should see a limited impact in 2019 and early 2020, and faces "incrementally more benefits" in the medium to longer term, contends the analyst. He believes industry dynamics are favorable and should allow the company to deliver "strong" growth into next year.
HQY HealthEquity
$58.00

-1.36 (-2.29%)

07/19/19
BOFA
07/19/19
UPGRADE
BOFA
Buy
HealthEquity upgraded to Buy from Neutral at BofA/Merrill
07/19/19
BOFA
07/19/19
UPGRADE
Target $90
BOFA
Buy
BofA sees 'too many tailwinds to ignore' at HealthEquity, upgrades to Buy
As previously reported, BofA Merrill Lynch analyst Allen Lutz upgraded HealthEquity (HQY) to Buy from Neutral, stating that he sees "too many tailwinds to ignore," including its WageWorks (WAGE) deal and the recent expansion of preventive care coverage in HDHPs. Additionally, he believes that interest rate fears are priced into the stock at current levels, Lutz tells investors. He raised his price target on HealthEquity shares to $90 from $75.
07/19/19
RAJA
07/19/19
NO CHANGE
Target $90
RAJA
Outperform
HealthEquity price target raised to $90 from $85 at Raymond James
Raymond James analyst Gregory Peters raised his price target for HealthEquity (HQY) to $90 from $85 and reiterates an Outperform rating on the shares. The analyst estimates the WageWorks (WAGE) acquisition should be accretive to non-GAAP earnings by 2% and 56% in fiscal 2020 and fiscal 2021, respectively.
07/15/19
STFL
07/15/19
DOWNGRADE
Target $51
STFL
Hold
WageWorks downgraded to Hold from Buy at Stifel
Stifel analyst David Grossman downgraded WageWorks (WAGE) to Hold from Buy with an unchanged price target of $51. The analyst does not envision a competing takeover offer for the company.
EGAN eGain
$7.56

0.35 (4.85%)

05/09/19
05/09/19
DOWNGRADE
Target $10

Hold
eGain downgraded to Hold after quarterly results at Craig-Hallum
As previously reported, Craig-Hallum analyst Jeff Van Rhee downgraded eGain to Hold from Buy following quarterly results as he awaits a more attractive risk/reward profile. The analyst has increased concerns around churn and the attractiveness of the platform to new customers. He also lowered his price target on the shares to $10 from $12.
09/07/18
ROTH
09/07/18
NO CHANGE
Target $16
ROTH
Buy
eGain FY19 guidance looks conservative, says Roth Capital
Roth Capital analyst Richard Baldry noted that eGain's initial FY19 guidance was moderately below his forecast, but he also believes that it appears conservative as he sees the company being positioned to at least grow SaaS revenues on par with FY18, and perhaps better. He reiterates a Buy rating and $16 price target on eGain shares.
05/09/19
CHLM
05/09/19
DOWNGRADE
CHLM
Hold
eGain downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Jeff Van Rhee downgraded eGain to Hold from Buy following the company's Q3 earnings report.
SUP Superior Industries
$2.61

-0.14 (-5.09%)

02/13/19
GHSC
02/13/19
INITIATION
GHSC
Neutral
Superior Industries initiated with a Neutral at Seaport Global
02/08/19
BWSF
02/08/19
NO CHANGE
Target $6
BWSF
Buy
Superior Industries price target lowered to $6 from $10 at BWS Financial
BWS Financial analyst Vahid Khorsand lowered his price target for Superior Industries to $6 and keeps a Neutral rating on the shares. Superior remains vulnerable to persistent reports of a slowdown in North America and European auto sales, Khorsand tells investors in a research note. He points out that new reports suggest both markets are now slowing. The analyst fears Superior Industries could have a difficult time generating free cash flow in such an environment in 2019.
11/14/18
11/14/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Aramark (ARMK) upgraded to Outperform from Neutral at Baird analyst Andrew Wittmann citing its recent underperformance, improving free cash flow, roughly 10% earnings growth, synergy benefits, and a steadier business model. 2. CAE (CAE) upgraded to Outperform from Neutral at Macquarie. 3. TD Ameritrade (AMTD) upgraded to Overweight from Equal Weight at Morgan Stanley analyst Michael Cyprys saying he favors discount brokers in a more volatile, late cycle environment. 4. Amarin (AMRN) upgraded to Buy from Neutral at Citi with analyst Joel Beatty citing limited upside to his price target and increased investor expectations. 5. Superior Industries (SUP) upgraded to Buy from Neutral at Buckingham with analyst Glenn Chin saying Q3 results were inline with pre-announced results and the subsequent sell-off is overdone. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/18
BUCK
11/14/18
UPGRADE
Target $12
BUCK
Buy
Superior Industries upgraded to Buy from Neutral at Buckingham
Buckingham analyst Glenn Chin upgraded Superior Industries to Buy from Neutral and lowered its price target to $12 from $19. Chin said Q3 results were inline with pre-announced results and the subsequent sell-off is overdone. The analyst expects higher input costs, lower European production, and high launch costs to subside in future quarters and to continue to benefit from the trend to larger, more complex wheels which tend to be higher revenue and profit/wheel.
ARDS Aridis Pharmaceuticals
$11.01

-1.39 (-11.21%)

09/10/18
LDLW
09/10/18
INITIATION
Target $23
LDLW
Buy
Aridis Pharmaceuticals initiated with a Buy at Laidlaw
Laidlaw analyst Francois Brisebois started Aridis Pharmaceuticals with a Buy rating and $23 price target. The analyst believes the company's "fairly late stage differentiated clinical pipeline" could more efficiently fulfill unmet medical and financial needs.
10/02/18
MAXM
10/02/18
INITIATION
MAXM
Buy
Aridis Pharmaceuticals initiated with a Buy at Maxim
09/10/18
09/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NMI Holdings (NMIH) initiated with an Overweight at Barclays. 2. Aridis Pharmaceuticals (ARDS) initiated with an Outperform at Northland, an Overweight at Cantor Fitzgerald, and a Buy at Laidlaw. 3. Central Garden & Pet (CENT) initiated with a Buy at BofA/Merrill. 4. GDS Holdings (GDS) initiated with an Outperform at Cowen. 5. Overstock.com (OSTK) assumed with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/18
NORL
09/10/18
INITIATION
Target $40
NORL
Outperform
Aridis Pharmaceuticals initiated with an Outperform at Northland
Northland analyst Carl Byrns initiated Aridis Pharmaceuticals with an Outperform and $40 price target.
RWT Redwood Trust
$16.67

0.06 (0.36%)

03/26/19
NOMU
03/26/19
INITIATION
Target $17.5
NOMU
Buy
Redwood Trust initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Matthew Howlett started Redwood Trust with a Buy rating and $17.50 price target. The analyst says the recent dissipation of the company's premium valuation has created an opportunity for investors. He initiated coverage of the U.S. Mortgage REITs industry with a positive outlook. The environment for levered mortgage-based operating models is the best it's been since the Taper Tantrum, Howlett tells investors in a research note. He thinks the space is poised to attract interest from "yield-starved investors amid a low, range-bound interest rate environment and expected yield curve steepening."
03/04/19
BARD
03/04/19
UPGRADE
BARD
Outperform
Redwood Trust upgraded to Outperform from Neutral at Baird
03/04/19
JMPS
03/04/19
UPGRADE
Target $17
JMPS
Outperform
Redwood Trust upgraded to Outperform from Market Perform at JMP Securities
JMP Securities analyst Steven DeLaney upgraded Redwood Trust to Outperform from Market Perform and set a $17 price target on the shares, telling investors that he consider the current valuation an unwarranted discount to hybrid MREIT peers. He also said that based on management commentary in the QQ4 shareholder letter that it appears providing a sustainably higher dividend payout is a priority for new management.
02/05/19
FBCO
02/05/19
INITIATION
Target $18
FBCO
Outperform
Redwood Trust initiated with an Outperform at Credit Suisse
Credit Suisse analyst Douglas Harter started coverage of Redwood Trust with an Outperform rating and $18 price target. The analyst believes the company's differentiated business model and its risk management history warrant a premium valuation over traditional mREITs. Harter forecasts a 20% TR opportunity over the next 12 months.
OKTA Okta
$128.18

1.66 (1.31%)

08/29/19
ADAM
08/29/19
NO CHANGE
Target $145
ADAM
Buy
Okta price target raised to $145 from $125 at Canaccord
Canaccord analyst Richard Davis raised his price target on Okta to $145 from $125 following exceptional Q2 results. The analyst cited its solid execution and secular story and he believes investors should maintain their positions for future gains. the company has its Okta showcase event in October which should shed light on product momentum and additional platform enhancements. Davis reiterated his Buy rating on Okta shares.
08/29/19
DADA
08/29/19
NO CHANGE
Target $131
DADA
Neutral
Okta price target raised to $131 from $114 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on Okta to $131 after its "strong" Q2 driven by the success of the company's newer products and the momentum with its large deals. The analyst is also positive on Okta's reported subscription revenue and billings growth, but keeps his rating on the stock at Neutral, stating that while its business is "firing on all cylinders", its valuation is "too rich".
08/29/19
JPMS
08/29/19
NO CHANGE
Target $168
JPMS
Overweight
Okta price target raised to $168 from $127 at JPMorgan
JPMorgan analyst Sterling Auty raised his price target for Okta to $168 from $127 following the company's Q2 results saying its "impressive growth continues." Customer deal sizes grew on the back of larger initial deployments and customers taking down a greater portion of the product portfolio, Auty tells investors in a research note. Further, he believes the shift to the cloud by companies across industries will provide the backdrop for additional growth. The analyst keeps an Overweight rating on Okta shares.
08/29/19
MSCO
08/29/19
NO CHANGE
Target $117
MSCO
Equal Weight
Okta price target raised to $117 from $107 at Morgan Stanley
Morgan Stanley analyst Melissa Franchi raised her price target for Okta to $117 from $107 saying the company sustained its strong enterprise momentum in Q2. Contrary to growing macro concerns across security and broader IT spending, Okta reported "solid" 52% year-over-year growth in current remaining performance obligations bookings, Franchi tells investors in a research note. The analyst, however, sees a balanced risk/reward at current valuation levels and keeps an Equal Weight rating on Okta shares.

TODAY'S FREE FLY STORIES

FIT

Fitbit

$3.73

0.06 (1.64%)

14:03
09/20/19
09/20
14:03
09/20/19
14:03
Periodicals
Breaking Periodicals news story on Fitbit »

Fitbit in talks with bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$122.80

-5.865 (-4.56%)

13:55
09/20/19
09/20
13:55
09/20/19
13:55
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$52.26

-0.8 (-1.51%)

13:53
09/20/19
09/20
13:53
09/20/19
13:53
Conference/Events
Dell Technologies to hold a business news update meeting »

CFO Sweet, along with SVP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Nov

FTR

Frontier Communications

$1.00

-0.0006 (-0.06%)

13:43
09/20/19
09/20
13:43
09/20/19
13:43
Periodicals
Frontier Communications prepares for debt restructuring talks, WSJ reports »

Frontier Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
09/20/19
09/20
13:40
09/20/19
13:40
General news
U.S. equity markets »

U.S. equity markets were…

BTU

Peabody Energy

$15.47

-1.56 (-9.16%)

, ARCH

Arch Coal

$71.00

-5.37 (-7.03%)

13:39
09/20/19
09/20
13:39
09/20/19
13:39
Hot Stocks
Peabody Energy confirms commitment to pending PRB/Colorado joint venture »

Peabody (BTU) confirmed…

BTU

Peabody Energy

$15.47

-1.56 (-9.16%)

ARCH

Arch Coal

$71.00

-5.37 (-7.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SPY

SPDR S&P 500 ETF Trust

$298.09

-1.586381 (-0.53%)

, SPX

S&P 500

$0.00

(0.00%)

13:34
09/20/19
09/20
13:34
09/20/19
13:34
Periodicals
Chinese delgation cancels farm trip to Montana, Reuters reports »

Chinese officials that…

SPY

SPDR S&P 500 ETF Trust

$298.09

-1.586381 (-0.53%)

SPX

S&P 500

$0.00

(0.00%)

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

NDX

Nasdaq 100 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$151.80

-1.95 (-1.27%)

13:30
09/20/19
09/20
13:30
09/20/19
13:30
Options
Trader trims risk by legging out of iron condor in Ferrari »

Trader trims risk by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$29.05

-0.01 (-0.03%)

13:25
09/20/19
09/20
13:25
09/20/19
13:25
Options
MGM Resorts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$300.00

0.323619 (0.11%)

, SPX

S&P 500

$0.00

(0.00%)

13:22
09/20/19
09/20
13:22
09/20/19
13:22
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Montana farm bureau says…

SPY

SPDR S&P 500 ETF Trust

$300.00

0.323619 (0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$117.62

0.58 (0.50%)

, MO

Altria Group

$41.19

1.08 (2.69%)

13:21
09/20/19
09/20
13:21
09/20/19
13:21
Periodicals
Walmart to stop sale of e-cigarettes in stores, Yahoo Finance reports »

Walmart (WMT) will stop…

WMT

Walmart

$117.62

0.58 (0.50%)

MO

Altria Group

$41.19

1.08 (2.69%)

BTI

British American Tobacco

$36.57

0.07 (0.19%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$72.77

1.07 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

MGM

MGM Resorts

$29.04

-0.02 (-0.07%)

13:21
09/20/19
09/20
13:21
09/20/19
13:21
Periodicals
Breaking Periodicals news story on MGM Resorts »

MGM Resorts in talks to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTI

British American Tobacco

$36.57

0.07 (0.19%)

, MO

Altria Group

$41.24

1.13 (2.82%)

13:19
09/20/19
09/20
13:19
09/20/19
13:19
Hot Stocks
BTI says product, to its knowledge, not involved in vaping deaths »

British American Tobacco…

BTI

British American Tobacco

$36.57

0.07 (0.19%)

MO

Altria Group

$41.24

1.13 (2.82%)

PM

Philip Morris

$72.78

1.08 (1.51%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/20/19
09/20
13:17
09/20/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/20/19
09/20
13:16
09/20/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$20.74

-0.17 (-0.81%)

13:15
09/20/19
09/20
13:15
09/20/19
13:15
Periodicals
Fluor seen announcing cost cuts, possible dividend cut, blog report says »

When Fluor announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

WMT

Walmart

$117.59

0.55 (0.47%)

, BTI

British American Tobacco

$36.62

0.12 (0.33%)

13:13
09/20/19
09/20
13:13
09/20/19
13:13
Periodicals
Walmart to stop sale of e-cigarettes in stores, Reuters says »

Publicly traded tobacco…

WMT

Walmart

$117.59

0.55 (0.47%)

BTI

British American Tobacco

$36.62

0.12 (0.33%)

MO

Altria Group

$41.20

1.09 (2.72%)

PM

Philip Morris

$72.77

1.07 (1.49%)

IMBBY

Imperial Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

F

Ford

$9.29

0.185 (2.03%)

, GM

General Motors

$37.72

-0.06 (-0.16%)

13:09
09/20/19
09/20
13:09
09/20/19
13:09
Hot Stocks
California, 23 other states sue NHTSA over Trump preemption rule »

California Attorney…

F

Ford

$9.29

0.185 (2.03%)

GM

General Motors

$37.72

-0.06 (-0.16%)

HMC

Honda

$26.80

0.15 (0.56%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$137.04

0.44 (0.32%)

TSLA

Tesla

$242.52

-3.99 (-1.62%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.59

-0.04 (-0.29%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 23

    Oct

  • 23

    Oct

13:03
09/20/19
09/20
13:03
09/20/19
13:03
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 9/20 Baker-Hughes…

BHGE

Baker Hughes

$23.08

-0.13 (-0.56%)

13:02
09/20/19
09/20
13:02
09/20/19
13:02
Hot Stocks
Baker Hughes reports U.S. rig count down 18 to 868 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSTM

Verastem

$1.31

0.01 (0.77%)

13:01
09/20/19
09/20
13:01
09/20/19
13:01
Hot Stocks
Verastem says to present abstracts on Phase 3 DUO study data »

Verastem announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

NFLX

Netflix

$268.50

-18.08 (-6.31%)

, AMZN

Amazon.com

$1,800.89

-21.32 (-1.17%)

12:54
09/20/19
09/20
12:54
09/20/19
12:54
Periodicals
Netflix CEO sees 'whole new world' in November with Apple, Disney launches »

Netflix (NFLX) CEO Reed…

NFLX

Netflix

$268.50

-18.08 (-6.31%)

AMZN

Amazon.com

$1,800.89

-21.32 (-1.17%)

AAPL

Apple

$220.41

-0.5 (-0.23%)

DIS

Disney

$132.31

-1.01 (-0.76%)

CMCSA

Comcast

$46.70

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 16

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

YCBD

cbdMD

$4.99

0.27 (5.72%)

12:50
09/20/19
09/20
12:50
09/20/19
12:50
Hot Stocks
Breaking Hot Stocks news story on cbdMD 

cbdMD trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LL

Lumber Liquidators

$9.30

0.41 (4.61%)

12:47
09/20/19
09/20
12:47
09/20/19
12:47
Hot Stocks
Whitney Tilson 'bullish as ever' on Lumber Liquidators, sees potential double »

Whitney Tilson of Empire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
09/20/19
09/20
12:45
09/20/19
12:45
General news
Breaking General news story  »

Week of 9/20 Baker-Hughes…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.